GlassScriptPhysician profile
Kenneth G Smith
NPI 1700098324
$4,894.57
in general payments reported to CMS, 2019-2025
32 companies · $1,176 in 2025
The $1,176 reported for 2025 was more than what 81% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $350 · 2020: $520 · 2021: $567 · 2022: $699 · 2023: $857 · 2024: $725 · 2025: $1,176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,733 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,733.38 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $531.13 | 2019-2025 | Jynarque, Voyxact |
| Astrazeneca Pharmaceuticals LP | $520.91 | 2019-2024 | Farxiga, Lokelma |
| Fresenius USA Marketing, INC. | $428.41 | 2019-2025 | Velphoro, Velphoro |
| Bayer Healthcare Pharmaceuticals INC. | $407.59 | 2022-2025 | |
| Vifor Pharma, INC. | $347.80 | 2019-2023 | Veltassa, Korsuva |
| Mallinckrodt Hospital Products INC. | $338.21 | 2021-2025 | Acthar, Terlivaz |
| Amgen INC. | $334.06 | 2019-2025 | Tavneos, Krystexxa, Parsabiv |
| Novartis Pharmaceuticals Corporation | $317.54 | 2020-2025 | |
| Akebia Therapeutics INC | $287.05 | 2019-2024 | Auryxia, Vafseo |
| Calliditas Therapeutics US INC. | $235.05 | 2022-2025 | Tarpeyo |
| Opko Pharmaceuticals, LLC | $132.44 | 2019-2024 | Rayaldee |
| Daiichi Sankyo INC. | $126.64 | 2020-2025 | Injectafer |
| Alexion Pharmaceuticals, INC. | $120.91 | 2019-2025 | Ultomiris |
| Baxter Healthcare | $120.22 | 2023 | |
| Medtronic, INC. | $92.35 | 2021-2023 | Ellipsys Vascular Access System |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.89 | 2024-2025 | Jardiance |
| Aurinia Pharma U.S., INC. | $66.36 | 2021-2022 | |
| Horizon Therapeutics Plc | $56.11 | 2019-2023 | Krystexxa |
| Ani Pharmaceuticals, INC. | $48.70 | 2022-2024 | Purified Cortrophin Gel |
| Genzyme Corporation | $39.72 | 2023-2025 | |
| Lilly USA, LLC | $37.34 | 2024-2025 | Jardiance |
| Glaxosmithkline, LLC. | $37.12 | 2021-2022 | |
| Ardelyx, INC. | $30.20 | 2024-2025 | Ibsrela |
| Pharmacosmos Therapeutics INC. | $20.91 | 2021 | |
| Idorsia Pharmaceuticals US INC | $19.86 | 2025 | Tryvio |
| Novo Nordisk INC | $19.71 | 2025 | Ozempic, Rybelsus |
| Seqirus USA INC | $18.82 | 2019 | |
| Pfizer INC. | $18.55 | 2023 | |
| Mallinckrodt Enterprises LLC | $18.08 | 2019 | |
| Amicus Therapeutics, INC. | $17.20 | 2023 | Galafold |
| Xeris Pharmaceuticals, INC. | $15.59 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $15.10 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.